FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895800948> ?p ?o ?g. }

• W2895800948 endingPage "80" @default.
• W2895800948 startingPage "74" @default.
• W2895800948 abstract "Aim. To assess the efficacy and tolerance of certolizumab pegol (CP) in patients with Crohn's disease (CD) treated in the Department of inflammatory bowel diseases of the A.S. Loginov Moscow Clinical Research Center and to determine the predictors of response to therapy. Materials and methods. All patients with CD who had received the treatment of CP were observed prospectively for at least 6 months or until the date of discontinuation of the drug. The effectiveness of the study was assessed response to therapy by the 6th week, maintaining the clinical response (6th and 26th weeks), the dynamics of endoscopic parameters by the 10th and 54th week of therapy, long-term maintenance of remission, healing fistula. Used univariant and multivariate analyses of predictors of response to treatment. Results and discussion. The study included 39 patients: 12 (30.7%) men and 27 (69.3%) female, the average duration of observation was 104 weeks. The interdepartmental range was in the range from 28 to 158 weeks. Clinical improvement occurred in 38 out of 39 (97.4 %) patients with CD. Comparative analysis of response to treatment with CP have bionaive patients previously treated with another inhibitor of TNF-α. In the group of bionaive response to therapy in a month, 6 months and at the end of the observation period occurred at 100.0%, 95.0% and 95.0%, respectively. In the group of patients previously treated with GSI, the response rate was about 94.4 %, 88.9 % and 77.7% week 54 endoscopic response and endoscopic remission was maintained in 46,2% and 30,1% patients, complete healing of the mucosa on the background of maintenance therapy, CP, was preserved in 20.5% of patients with Crohn's disease. In the group of patients with perianal lesions (n=13) complete closure of all fistulas was observed in 5 (38.6 %) patients, partial response was observed in 4 patients (30,7%) patients, in 4 (30.7 %) closure of fistulas occurred. The frequency of adverse events was 0 cases (0.0%). The dose escalation was required in 3 patients (7,7%) patients with CD. Dose escalation in our study required patients with high initial CDAI and previous inefficiencies of the other two inhibitors of TNF-α. Reliable predictors of secondary loss of response and need for dose escalation of the drug has been the continued level of CRP >5 mg/l after 2 weeks initiation of therapy CP and smoking. Conclusion. The obtained results demonstrate the efficacy and tolerability profile of CP appropriate for long-term CD therapy in real clinical practice." @default.
• W2895800948 created "2018-10-26" @default.
• W2895800948 creator A5005798869 @default.
• W2895800948 creator A5008537723 @default.
• W2895800948 creator A5008601428 @default.
• W2895800948 creator A5014716101 @default.
• W2895800948 creator A5036687613 @default.
• W2895800948 creator A5056819802 @default.
• W2895800948 creator A5071693872 @default.
• W2895800948 date "2018-06-15" @default.
• W2895800948 modified "2023-10-16" @default.
• W2895800948 title "Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice" @default.
• W2895800948 cites W1572018981 @default.
• W2895800948 cites W2049836762 @default.
• W2895800948 cites W2055851996 @default.
• W2895800948 cites W2073544361 @default.
• W2895800948 cites W2098931598 @default.
• W2895800948 cites W2605493496 @default.
• W2895800948 cites W2623453086 @default.
• W2895800948 cites W2769684727 @default.
• W2895800948 cites W2782361381 @default.
• W2895800948 cites W956151386 @default.
• W2895800948 doi "https://doi.org/10.26442/terarkh201890674-80" @default.
• W2895800948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30701908" @default.
• W2895800948 hasPublicationYear "2018" @default.
• W2895800948 type Work @default.
• W2895800948 sameAs 2895800948 @default.
• W2895800948 citedByCount "3" @default.
• W2895800948 countsByYear W28958009482020 @default.
• W2895800948 countsByYear W28958009482021 @default.
• W2895800948 crossrefType "journal-article" @default.
• W2895800948 hasAuthorship W2895800948A5005798869 @default.
• W2895800948 hasAuthorship W2895800948A5008537723 @default.
• W2895800948 hasAuthorship W2895800948A5008601428 @default.
• W2895800948 hasAuthorship W2895800948A5014716101 @default.
• W2895800948 hasAuthorship W2895800948A5036687613 @default.
• W2895800948 hasAuthorship W2895800948A5056819802 @default.
• W2895800948 hasAuthorship W2895800948A5071693872 @default.
• W2895800948 hasBestOaLocation W28958009481 @default.
• W2895800948 hasConcept C126322002 @default.
• W2895800948 hasConcept C141071460 @default.
• W2895800948 hasConcept C197934379 @default.
• W2895800948 hasConcept C2776215756 @default.
• W2895800948 hasConcept C2776694085 @default.
• W2895800948 hasConcept C2777138892 @default.
• W2895800948 hasConcept C2778283404 @default.
• W2895800948 hasConcept C2778375690 @default.
• W2895800948 hasConcept C2778715236 @default.
• W2895800948 hasConcept C2779134260 @default.
• W2895800948 hasConcept C2779280984 @default.
• W2895800948 hasConcept C2780132546 @default.
• W2895800948 hasConcept C71924100 @default.
• W2895800948 hasConcept C90924648 @default.
• W2895800948 hasConceptScore W2895800948C126322002 @default.
• W2895800948 hasConceptScore W2895800948C141071460 @default.
• W2895800948 hasConceptScore W2895800948C197934379 @default.
• W2895800948 hasConceptScore W2895800948C2776215756 @default.
• W2895800948 hasConceptScore W2895800948C2776694085 @default.
• W2895800948 hasConceptScore W2895800948C2777138892 @default.
• W2895800948 hasConceptScore W2895800948C2778283404 @default.
• W2895800948 hasConceptScore W2895800948C2778375690 @default.
• W2895800948 hasConceptScore W2895800948C2778715236 @default.
• W2895800948 hasConceptScore W2895800948C2779134260 @default.
• W2895800948 hasConceptScore W2895800948C2779280984 @default.
• W2895800948 hasConceptScore W2895800948C2780132546 @default.
• W2895800948 hasConceptScore W2895800948C71924100 @default.
• W2895800948 hasConceptScore W2895800948C90924648 @default.
• W2895800948 hasIssue "6" @default.
• W2895800948 hasLocation W28958009481 @default.
• W2895800948 hasLocation W28958009482 @default.
• W2895800948 hasOpenAccess W2895800948 @default.
• W2895800948 hasPrimaryLocation W28958009481 @default.
• W2895800948 hasRelatedWork W115503016 @default.
• W2895800948 hasRelatedWork W1970547942 @default.
• W2895800948 hasRelatedWork W1981107863 @default.
• W2895800948 hasRelatedWork W2147108849 @default.
• W2895800948 hasRelatedWork W2336578202 @default.
• W2895800948 hasRelatedWork W2504326190 @default.
• W2895800948 hasRelatedWork W2794241916 @default.
• W2895800948 hasRelatedWork W3107358738 @default.
• W2895800948 hasRelatedWork W2188685377 @default.
• W2895800948 hasRelatedWork W2189383814 @default.
• W2895800948 hasVolume "90" @default.
• W2895800948 isParatext "false" @default.
• W2895800948 isRetracted "false" @default.
• W2895800948 magId "2895800948" @default.
• W2895800948 workType "article" @default.